Gritstone's two vaccines Granite and Slate get positive safety data in Phase 1 clinical trials

recently, Gritstone(http:// announcedthat its two vaccines, Granite and Slate, based on new tumor antigens, were developed to obtain positive iogenic activity and safety data in the phase 1 clinicaltrial(http://Both the Granite individualized cancer vaccine developed by Gritstone and the Slate ready-to-use cancer vaccine were developed on the basis of its proprietary EDGE artificial intelligence platform and tumor HLA peptide sequenceThe EDGE platform has a wealth of human tumor data designed to predict tumor-specific new antigens (TSNAs) present in patients with routine tumor biopsiesSlate and Granite use the same development platform, but it contains a fixed set of shared new antigens, which are available in some cancer patients with the same mutation and are a ready-to-use cancer vaccineCurrently, both vaccines are combined with checkpoint inhibitors to treat patients with common solid tumors in Phase 1/2 clinical trialsIn a study called GO-004, two patients with gastroesophageal pancreatic cancer and one non-small cell lung cancer patient who had previously received anti-PD-L1 therapy were added to the first queue of the trial, and one MSS CRC patient was added to the second queue of the trial, all of whom received granite in combination with checkpoint inhibitorsIn a study called GO-005, patients involved in the trial were treated in combination with Slate and checkpoint inhibitors, and patients are still in the early stages of treatmentPreliminary results show that the two vaccines are well tolerated and safeIn the GO-004 study, the lowest dose of Granite can quickly and steadily activate new antigen-specific CD8-positive T cellsThese T-cells are also able to produce IL-2 and Granzyme B, indicating that they are cytotoxic